



Auro Laboratories Limited

314, T. V. Industrial Estate, S.K. Ahire Marg,
Worli, Mumbai - 400 030, India
Tel. : + 91 22 6663 5456
Fax : +91 22 6663 5460
E-mail : auro@aurolabs.com
Web : www.aurolabs.com

Reg. Off. / Mfg. Unit :
K-56, M. I. D. C. Tarapur,
Dist. Palghar, Maharashtra - 401506.
CIN No. L33125MH1989PLC051910

Date: August 13, 2018

To
Corporate Relationship Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001

Reg: Security Code No. 530233

Sub: Outcome of the Board Meeting

Dear Sir/Ma'am,

Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its Meeting held today i.e. August 13, 2018 inter-alia, considered following matters.

1. Approved Un-audited Financial Results for the quarter ended June 30, 2018 in accordance with the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

In this regards, we are enclosing herewith:

- Un-audited Financial Results for the Quarter ended June 30, 2018.
 - Limited Review Report received from the Statutory Auditor of the Company.
2. The 29th Annual General Meeting of the Company will be held on Saturday, September 29, 2018.
 3. Approved Notice & Directors Reports' alongwith the annexures for the Financial Year ended March 31, 2018.
 4. Re-appointment of Mr. Govardhan Das Agarwal, Independent Director for a Second term of 5 consecutive years, w.e.f. April 1, 2019, subject to approval of members at the ensuing Annual General Meeting.

5. Re-appointment of Mr. Kailash Chandra Bubna, Independent Director for a Second term of 5 consecutive years, w.e.f. April 1, 2019, subject to approval of members at the ensuing Annual General Meeting.

The Meeting of the Board of Directors commenced at 2.30 P. M. and concluded at 3.15 P. M..

The results will be published in the newspaper pursuant to Regulation 47(1)(b) of SEBI (LODR) Regulations, 2015 in due course.

Kindly take the same on record and acknowledge.

Thanking You,

Yours Faithfully,

For AURO LABORATORIES LIMITED





SHARAT DEORAH
CHAIRMAN & MANAGING DIRECTOR
(DIN: 00230784)

Encl.: as above

ANNEXURE - I

PART - I		Rs. In Lakh except EPS)			
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2018					
Sr. No.	Particulars	3 Months ended	Preceding 3	Corresponding	Year Ended
		30.06.2018 (Unaudited)	Months ended 31.03.2018 (Audited)	3 Months ended in the Previous Year (Unaudited)	31.03.2018 (Audited)
1	Income from Operations				
	(a) Net Sales/Income from Operations (Net)	1,046.78	1127.82	752.46	4079.40
2	Other Income	3.09	22.65	2.64	51.39
3	Total Revenue (1 + 2)	1,049.87	1,150.47	755.10	4,130.79
4	Expenses				
	a Consumption of raw material	716.41	660.79	579.35	2461.65
	b Purchase of Stock-in-trade	1.04	1.24	-	4.06
	c (Increase) / decrease in Finished Goods stock in trade and work in progress	(65.90)	(92.49)	(121.17)	6.24
	d Employee benefits expense	86.65	171.92	72.32	369.54
	e Finance Cost	22.80	5.03	29.89	108.85
	f Depreciation and amortisation expenses	24.50	20.11	22.00	93.11
	g Other Expenses	179.61	178.15	128.31	614.60
	Total Expenses (4)	965.11	944.75	710.70	3,658.05
5	Profit / (Loss) before exceptional and extraordinary items and tax (3 ± 4)	84.76	205.72	44.40	472.74
6	Exceptional items				
7	Profit / (Loss) before extraordinary items and tax (5 ± 6)	84.76	205.72	44.40	472.74
8	Extraordinary items				
9	Profit / (Loss) before tax (7 ± 8)	84.76	205.72	44.40	472.74
10	Tax expense				
	(a) Current tax expenses for current year	21.19	-	-	127.34
	(b) MAT credit (where applicable)	-	-	-	-
	(c) Defferered tax	-	-	-	(7.56)
11	Profit / (Loss) for the period from continuing operation (9± 10)	63.57	205.72	44.40	352.96
12	Profit / (Loss) for discontinuing operations				
13	Tax expense of discontinuing operations				
14	Profit / (Loss) for discontinuing operation (after tax) (12 ± 13)	63.57	205.72	44.40	352.96
15	Other Comprehensive Income	17.52	2.75	9.43	4.63
16	Total Comprehensive Income for the period (14 ± 15)	81.49	208.47	53.83	357.59
17	Paid-up equity share capital (Face value of Rs. 10 each)	623.25	623.25	623.25	623.25
18	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year)				251.30
19	Earnings per share (EPS) (Face Value - Rs. 10 per Equity Shares):				
	(a) Basic	1.02	3.30	0.71	5.66
	(b) Diluted	1.02	3.30	0.71	5.66

Notes:

- 1) The above unaudited financial results for the quarter ended 30th June, 2018 were reviewed by the Audit Committee and thereafter approved by the Board of Directors at meeting held on 13th August 2018
- 2) The Company operates in single segment i.e. "Pharmaceuticals", and hence does not have any additional disclosures to be made under Ind As 108 on operating Segments
- 3) Consequent to implementation of the goods and Service Tax (GST) with effect from July 1, 2017, presentation of revenue for the Quarters after that date excludes GST and hence not comparable with periods which includes Excise Duty.
- 4) Figures for the quarter ended March 31, 2018 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures of nine months ended December 31, 2017.
- 5) Limited review has been carried out by the Statutory Auditors of the Company.
- 6) Figures of previous period have regrouped / reclassified wherever necessary to facilitate comparison.

FOR & BEHALF OF BOARD OF DIRECTORS
AURO LABORATORIES LIMITED

SHARAT DEORAH
CHAIRMAN & MANAGING DIRECTOR.
DIN NO. 00230784

Place : Mumbai
Date : 13.08.2018



KHURDIA JAIN & CO.
CHARTERED ACCOUNTANTS


To,
The Board of Directors,
Auro Laboratories Limited.

We have reviewed the standalone Ind AS financial results of Auro Laboratories Ltd. ("the company") for the quarter ended June 30, 2018, attached herewith, being submitted by the company pursuant to the requirement of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. "CIR/CFD/FAC/62/2016" dated July 05, 2016 and "CIR/IMD/DF1/69/2016" dated August 10, 2016.

This Statement is the responsibility of the Company's Management and had been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards, prescribed under section 133 of the Companies Act 2013 read with relevant rules issued thereunder and accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statements prepared in accordance with generally accepted accounting standards in India and other recognized accounting practices and policies has not disclosed the information required to be disclosed in term of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as modified by Circular No. "CIR/CFD/FAC/62/2016" dated July 05, 2016 and "CIR/IMD/DF1/69/2016" dated August 10, 2016, including the manner in which it is to be disclosed or that it contains any material misstatement.

For Khurdia Jain & Co.
Chartered Accountants

Sampat Khurdia
Partner
Membership No. 33615
Firm Reg. No. 120263W
Place: Mumbai
Date: 13/08/2018

